Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease

doi:10.3748/wjg.v23.i3.414

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7523)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-7) series.

Item

Count

PDF

624

WORD

258

HTML

4026

Tables (1-7)

215

Sum=5123

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1155

Download

1245

Sum=2400

Jan 21, 2017 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jan 21, 2017; 23(3): 414-425
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.414

Table 5 Strategies to overcome loss of response

Dose escalate	Alternative cause for LOR?
Low trough	Adequate trough
No ADA	No ADA
Combination therapy	Alternative anti-TNFα/agent
Low trough	Low trough
ADA	ADA

ADA: Anti-TNFα; LOR: Loss of response.

Citation: Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 414-425
URL: https://www.wjgnet.com/1007-9327/full/v23/i3/414.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i3.414